The company has indicated that it expects “a fair decision” for the violation of a “series of intellectual property rights of more than two decades of pioneering work in mRNA technology.”
German biotech Curevac has filed a lawsuit in Germany against BioNTech, which produces the covid-19 vaccine, and two subsidiaries for patent infringement in relation to messenger RNA (mRNA) technology.
Curevac has reported this Tuesday that it expects “a fair decision” for the violation of a “series of intellectual property rights of more than two decades of pioneering work in mRNA technology” that have contributed to the development and sale of the vaccine against covid-19 Comirnaty of BioNTech and the American Pfizer.
CureVac has filed the lawsuit against BioNTech and two of its subsidiaries in the Düsseldorf Regional Court, but does not provide for an urgent appeal, nor does it want to take legal action that would prevent the production, sale or distribution of Comirnaty.
Several biotech companies have developed COVID-10 vaccines based on mRNA technology, which teaches cells to make a protein that triggers an immune response within the body.
